Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor–Positive, HER2-Negative Breast Cancer | Zendy

AI Assistant Blog Pricing

Open Access

Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor–Positive, HER2-Negative Breast Cancer

Author(s) -

Harmony Bowles,

Kathryn Clarke

Publication year - 2015

Publication title -

journal of the advanced practitioner in oncology

Language(s) - English

Resource type - Journals

eISSN - 2150-0886

pISSN - 2150-0878

DOI - 10.6004/jadpro.2015.6.6.6

Subject(s) - medicine , palbociclib , metastatic breast cancer , her2 negative , oncology , hormone receptor , breast cancer , front line , cancer , political science , law

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.